IRIS
PISTELLI, MIRCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 987
EU - Europa 363
AS - Asia 113
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 1.477
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 987
IT - Italia 84
SE - Svezia 69
IE - Irlanda 64
UA - Ucraina 57
CN - Cina 48
DE - Germania 35
SG - Singapore 35
GB - Regno Unito 16
TR - Turchia 16
DK - Danimarca 14
CI - Costa d'Avorio 11
FI - Finlandia 10
FR - Francia 9
KR - Corea 8
BE - Belgio 4
IN - India 4
EU - Europa 2
JP - Giappone 2
AU - Australia 1
RO - Romania 1
Totale 1.477
Salva come PNG Salva come JPEG
Città #
Chandler 170
Jacksonville 89
Ashburn 83
Fairfield 80
Dublin 63
Des Moines 54
Houston 41
New York 40
Woodbridge 40
Seattle 38
Wilmington 38
Boardman 32
Cambridge 27
Lawrence 22
Princeton 22
Ann Arbor 21
San Mateo 20
Centro 15
Beijing 12
San Diego 12
Abidjan 11
Turin 9
Washington 9
Porto 8
Singapore 7
Cagliari 6
Cantu 5
Chiaravalle 5
Falls Church 5
Brussels 4
Prescot 4
Pune 4
Guangzhou 3
Helsinki 3
Kilburn 3
London 3
Wuhan 3
Yiwu 3
Caserta 2
Chengdu 2
Marche 2
Osimo 2
Qingdao 2
Recanati 2
Redmond 2
Redwood City 2
Rome 2
Southwark 2
Ancona 1
Arqua Petrarca 1
Avant-lès-marcilly 1
Brisbane 1
Cedar Knolls 1
Civitanova Marche 1
Clifton 1
Dalian 1
Dangan 1
Duncan 1
Hounslow 1
Jinhua 1
Los Angeles 1
Mestre 1
Norwalk 1
Philadelphia 1
Phoenix 1
San Costanzo 1
Scafati 1
Shanghai 1
Shaoxing 1
Shenzhen 1
Sioux Falls 1
Suzhou 1
Verona 1
Wuxi 1
Totale 1.060
Salva come PNG Salva come JPEG
Nome #
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 101
Role of DCE-MR in predicting breast cancer subtypes. 97
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 92
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 88
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 84
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 84
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 79
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 73
Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit? 72
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report 71
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 69
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 68
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors 60
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 60
Adjuvant Systemic Therapy in DCIS 60
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 59
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 56
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 55
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 53
Espressione di p-mTOR e del recettore degli androgeni nei tumori mammari triplo negativi: significato clinico e potenziali prospettive terapeutiche 49
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 47
A Mixed-apprOach program To help women wIth breast cancer stay actiVE (MOTIVE program): A pilot-controlled study 43
Totale 1.520
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020120 2 1 10 1 15 0 10 4 11 14 15 37
2020/2021355 30 34 64 1 29 26 22 28 32 39 33 17
2021/2022184 12 28 4 1 2 29 11 9 17 22 17 32
2022/2023455 31 58 30 49 27 99 0 15 97 2 24 23
2023/2024241 46 3 16 17 33 70 4 16 0 2 0 34
2024/202551 51 0 0 0 0 0 0 0 0 0 0 0
Totale 1.520